Novartis rejects suspected data manipulation in US
Swiss pharmaceutical company Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to United States authorities for a human gene therapy.
This content was published on
1 minute
swissinfo.ch/ug
NovartisExternal link said its subsidiary in California began investigating the alleged data manipulation for its gene therapy Zolgensma as soon as it learned about it. Once the company had interim conclusions, it shared the informationExternal link with the US Food and Drug Administration (FDA).
The agency said Novartis did not disclose the information about suspected data manipulation until after the $2.1 million (CHF2.1) therapy treatment for children under the age of two won approval by the US regulator in May.
In a statement, the pharma company explained that the data in question were a small portion of its overall submission and limited to an older process no longer in use.
“The assays in question were used for initial product testing and are nor currently used for commercial product release,” Novartis said.
According to the company, Zolgensma, the most expensive treatment ever, is safe, of high quality and effective in treating patients with spinal muscular atrophy.
The FDA has indicated that the drug will remain on the market. The company’s actions are being assessed and could lead to criminal or civil penalties if appropriate.
More
More
How can a drug cost $2.1 million?
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
New gel developed in Zurich renders alcohol harmless
This content was published on
A newly developed gel composed of whey proteins breaks down alcohol in the body and could reduce its harmful and intoxicating effects in humans.
Pro-Palestine protests extend to Basel and Fribourg universities
This content was published on
Demonstrators called for an academic boycott of all Israeli institutions and disassociation with Chaim Weizmann, the first Israeli president.
This content was published on
In many cases, China's use of AI undermines the national security of the US and its allies, according to a US government representative.
Swiss Hells Angels trial alleges rape and money laundering
This content was published on
An allegedly high-ranking member of the Hells Angels is accused of money laundering totalling millions and rape, among other serious crimes.
SWISS is airline ‘group flagship’ says Lufthansa boss
This content was published on
Despite challenges, Lufthansa and its most important subsidiary, Swiss International Airlines, promise increased satisfaction and continued growth.
Swiss rediscover communist zeal after 84-year hiatus
This content was published on
Over 300 participants founded the Revolutionary Communist Party (RKP) at its congress in Burgdorf in canton Bern at the weekend.
This content was published on
Nemo brought the Eurovision Song Contest to Switzerland with a victory on Saturday evening in Malmö, Sweden. It is Switzerland's third victory in the history of the music contest.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
This content was published on
Swiss pharmaceutical Novartis must face a US government lawsuit accusing it of paying millions of dollars in kickbacks to doctors.
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
Novartis faces questions about proxy voting independence
This content was published on
Proxy votes submitted by shareholders ended up at Novartis headquarters instead of the elected representative ahead of the annual general meeting.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.